BELLEVILLE, ON, Dec. 15 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, has
taken note of a significant increase in volume of trading of its shares over
recent trading days. The Company has no undisclosed reportable developments.
It continues to pursue its strategic priorities: the completion of its Phase
III trials with its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) -
trademarked Urocidin - in bladder cancer; and the licensing of its E. coli
O157:H7 cattle vaccine.
